X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs ALKEM LABORATORIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA ALKEM LABORATORIES PLETHICO PHARMA/
ALKEM LABORATORIES
 
P/E (TTM) x -1.1 - - View Chart
P/BV x 0.0 6.2 0.3% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 PLETHICO PHARMA   ALKEM LABORATORIES
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
ALKEM LABORATORIES
Mar-16
PLETHICO PHARMA/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3951,589 24.9%   
Low Rs311,232 2.5%   
Sales per share (Unadj.) Rs604.4417.5 144.8%  
Earnings per share (Unadj.) Rs32.556.3 57.7%  
Cash flow per share (Unadj.) Rs51.364.7 79.3%  
Dividends per share (Unadj.) Rs012.70 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs473.6292.9 161.7%  
Shares outstanding (eoy) m34.08119.57 28.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.43.4 10.4%   
Avg P/E ratio x6.625.1 26.2%  
P/CF ratio (eoy) x4.221.8 19.0%  
Price / Book Value ratio x0.54.8 9.3%  
Dividend payout %022.6 0.0%   
Avg Mkt Cap Rs m7,262168,653 4.3%   
No. of employees `000NANA-   
Total wages/salary Rs m1,5969,171 17.4%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m20,59849,915 41.3%  
Other income Rs m3861,645 23.5%   
Total revenues Rs m20,98451,561 40.7%   
Gross profit Rs m2,8188,482 33.2%  
Depreciation Rs m6421,006 63.9%   
Interest Rs m1,593671 237.6%   
Profit before tax Rs m9698,451 11.5%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1381,606 -8.6%   
Profit after tax Rs m1,1076,731 16.4%  
Gross profit margin %13.717.0 80.5%  
Effective tax rate %-14.319.0 -75.2%   
Net profit margin %5.413.5 39.8%  
BALANCE SHEET DATA
Current assets Rs m18,87727,062 69.8%   
Current liabilities Rs m11,89615,324 77.6%   
Net working cap to sales %33.923.5 144.1%  
Current ratio x1.61.8 89.9%  
Inventory Days Days3667 54.0%  
Debtors Days Days19841 479.2%  
Net fixed assets Rs m9,86112,610 78.2%   
Share capital Rs m341239 142.5%   
"Free" reserves Rs m12,33134,490 35.8%   
Net worth Rs m16,13935,027 46.1%   
Long term debt Rs m4,7061,212 388.4%   
Total assets Rs m33,14654,387 60.9%  
Interest coverage x1.613.6 11.8%   
Debt to equity ratio x0.30 843.0%  
Sales to assets ratio x0.60.9 67.7%   
Return on assets %8.113.6 59.9%  
Return on equity %6.919.2 35.7%  
Return on capital %12.324.9 49.4%  
Exports to sales %21.412.9 165.1%   
Imports to sales %15.23.1 493.4%   
Exports (fob) Rs m4,4026,461 68.1%   
Imports (cif) Rs m3,1361,540 203.6%   
Fx inflow Rs m4,4026,563 67.1%   
Fx outflow Rs m3,1843,012 105.7%   
Net fx Rs m1,2193,552 34.3%   
CASH FLOW
From Operations Rs m2,4377,259 33.6%  
From Investments Rs m-6,2651,864 -336.1%  
From Financial Activity Rs m2,490-9,273 -26.9%  
Net Cashflow Rs m-1,337-150 891.4%  

Share Holding

Indian Promoters % 82.7 66.9 123.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 33.1 13.0%  
FIIs % 5.5 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 0.0 -  
Shareholders   10,665 68,381 15.6%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   TORRENT PHARMA  ALEMBIC PHARMA  ELDER PHARMA  SANOFI INDIA  DR. DATSONS LABS  

Compare PLETHICO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Infosys Woes, Insurance IPOs and Top Stocks in Action(Pre-Open)

On Monday, the share markets in India slumped in the final hours of trade and finished the day in red.The BSE Sensex closed lower by 266 points to end at 31,259.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 5-YR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS